Combination of lamivudine with thymosin alpha1 in treatment of duck hepatitis B.
- Author:
Xiang-ming CHEN
1
;
Zi-ming LIU
;
Xin-fang DU
;
Zheng-gang YANG
;
Xiao-ming CHEN
Author Information
- Publication Type:Journal Article
- MeSH: Animals; Animals, Newborn; Antiviral Agents; therapeutic use; Cells, Cultured; Drug Therapy, Combination; Ducks; Hepadnaviridae Infections; drug therapy; Hepatitis B Virus, Duck; drug effects; genetics; Hepatitis, Viral, Animal; drug therapy; Hepatocytes; virology; Lamivudine; therapeutic use; Thymosin; analogs & derivatives; therapeutic use; Virus Replication; drug effects
- From: Journal of Zhejiang University. Medical sciences 2005;34(2):121-125
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo explore the inhibitory effect of combination of lamivudine with thymosin alpha1 (Talpha1) on the replication of duck hepatitis B virus (DHBV).
METHODSPeking ducks of 1 d old were challenged with DHBV-positive serum and used as a duck hepatitis B model. After treated with lamivudine for three months, the ducks were randomly grouped and treated with or without Talpha1 for 8 d. Serum DHBV titrate was observed by semi-quantitative PCR, and inflammation and degeneration of hepatocytes were observed by pathology examination.
RESULTSThe serum DHBV titrate was significantly reduced (4483.2+/-5193.4 compared with 9351.8+/-5059.6) after lamivudine treatment, and it was reduced more significantly(1692.2+/-589.2) after combination treatment with Talpha1. Lamivudine reduced the degeneration degree of hepatocytes (3.2+/-0.8 compared with 4.6+/-0.5) and the inflammation degree of liver (6.2+/-3.3 compared with 8.6+/-2.8). The combination treatment with Talpha1 increased liver inflammation degree (9.0+/-5.2).
CONCLUSIONBoth Talpha1 and lamivudine may reduce the replication of DHBV in Peking ducks and combination treatment may have the better anti-virus effect and enhance immune response in liver.
